Last reviewed · How we verify
Infusion of MCARH109 T cells
Infusion of MCARH109 T cells is a Biologic drug developed by Memorial Sloan Kettering Cancer Center. It is currently in Phase 1 development.
At a glance
| Generic name | Infusion of MCARH109 T cells |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion of MCARH109 T cells CI brief — competitive landscape report
- Infusion of MCARH109 T cells updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI
Frequently asked questions about Infusion of MCARH109 T cells
What is Infusion of MCARH109 T cells?
Infusion of MCARH109 T cells is a Biologic drug developed by Memorial Sloan Kettering Cancer Center.
Who makes Infusion of MCARH109 T cells?
Infusion of MCARH109 T cells is developed by Memorial Sloan Kettering Cancer Center (see full Memorial Sloan Kettering Cancer Center pipeline at /company/memorial-sloan-kettering-cancer-center).
What development phase is Infusion of MCARH109 T cells in?
Infusion of MCARH109 T cells is in Phase 1.